Seralutinib clinical trials
Also written GB002.
How each study uses seralutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the seralutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. (3) · GB002, Inc. (2) · Gossamer Bio USA, Inc. (2) · Zhejiang Echon Biopharm Limited (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test seralutinib, phase 3 first.
- Dec 2026Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Phase 3 · Gossamer Bio USA, Inc.
Studies
Open first, then newest update. How each study uses seralutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)RecruitingPhase 3Gossamer Bio USA, Inc.NCT06274801Written as Seralutinib
- Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)TerminatedPhase 2Gossamer Bio USA, Inc.NCT04816604Written as GB002 (seralutinib)
- Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)CompletedPhase 3GB002, Inc.NCT05934526Written as Seralutinib
- Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)SuspendedPhase 3GB002, Inc.NCT07181382Written as Seralutinib
- Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsActive, not recruitingPhase 1Zhejiang Echon Biopharm LimitedNCT06423261Written as GB002 Recombinant Peptide Inhalation Solution
- GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)CompletedPhase 2GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.NCT04456998Written as GB002 (seralutinib)
- Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial HypertensionCompletedPhase 1GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.NCT03926793Written as GB002
- Phase 1A Safety Trial of Inhaled PK10571 (GB002)CompletedPhase 1GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.NCT03473236Written as GB002
Codes
What other systems call seralutinib · ClinicalTrials.gg INT014711
- UNII (FDA) 3P63ZTE3OYSERALUTINIBOne source FDA
- NCI Thesaurus C175203SeralutinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3P63ZTE3OY | SERALUTINIB | One source FDA |
| NCI Thesaurus | C175203 | Seralutinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.